康复新液联合雷贝拉唑三联疗法治疗消化性溃疡疗效及对炎性因子和血液流变学的影响  

Curative efficacy of kangfuxin solution in combination with rabeprazole-based triple therapy in the treatment of peptic ulcer and its effects on inflammatory factors and hemorheology

作　　者：巩俊卿[1] 鄢春风[2] 李莉[3] 

机构地区：[1]武警内蒙古总队医院门诊部,内蒙古呼和浩特010040 [2]武警内蒙古总队医院医务处,内蒙古呼和浩特010040 [3]武警内蒙古总队医院护理部,内蒙古呼和浩特010040

出　　处：《武警后勤学院学报（医学版）》2014年第12期993-996,共4页Journal of Logistics University of PAP（Medical Sciences）

摘　　要：【目的】探讨康复新液联合雷贝拉唑三联疗法治疗消化性溃疡(peptic ulcer,PU)的疗效及对患者炎性因子和血液流变学的影响。【方法】符合入选标准的80例PU患者按治疗方案随机分为观察组(n=40)和对照组(n=40)。对照组给予口服雷贝拉唑+阿莫西林+左氧氟沙星片,观察组在对照组的基础上加用康复新液。观察比较两组患者治疗效果、幽门螺杆菌(helicobacter pylori,Hp)根除率、炎性因子、血液流变学指标变化,记录不良反应发生情况。并随访1年,观察比较PU复发率。【结果】观察组治疗总有效率、Hp根除率为:97.5%、92.5%,对照组为:80.0%、87.5%,观察组治疗总有效率高于对照组(P<0.05),而Hp根除率两组间比较无统计学差异(P>0.05)。疗程结束后1周及2周时复查,观察组的炎性因子水平和血液流变学指标较对照组下降,且有统计学差异(P<0.05)。治疗过程中,两组不良反应轻微,不影响治疗。随访1年,观察组的PU复发率为2.6%,明显低于对照组21.9%(P<0.05)。【结论】康复新液联合雷贝拉唑三联疗法是治疗PU的有效方案,具有较高的临床缓解率,并能有效减轻炎性反应,改善血液流变学指标,降低复发率,临床上值得进一步研究。[Objective] To investigate the clinical effect of kangfuxin solution in combination with rabeprazole-based triple therapy in the treatment of peptic ulcer （PU） and its effects on inflammatory factors and hemorheology. [ MethOdS ] 80 cases of PU matching the inclusion criteria were randomly divided into 2 groups according to the therapeutic scheme. The control group was treated with rabeprazole＋amoxicillin＋ levofloxacin and the observation group was treated with kangfuxin solution and rabeprazole-based triple therapy. Then, the curative efficacy, eradicating rate of helicobacter pylori （Hp）, inflammatory factors, hemorheological parameters were observed and compared., adverse reactions were recorded and the recurrence rate were observed and compared during the one-year follow＇up [ Results ] The observation group had a therapeutic efficiency ratio of 97.5% and a Hp eradication rate of 92.5%, which was respectively statistically higher than that of 80.0% （P 〈 0.05） and statistically same with that of 87.5% （P 〉 0.05） in the control group. Compared with the control group one week and two weeks after the treatment, inflammatory factors of TNF-α, IL-6, CRP and hemorheological parameters of hematocrit, plasma viscosity, erythrocyte aggregation index, erythrocyte sedimentation rate was significantly lower respectively in the observation group （P 〈 0.05）. During the treatment, mild adverse reactions and no influence on the treatment occurred in the two groups. In the one-year follow-up, the observation group had a recurrence rate of 2.6%, which was significantly lower than that of 21.9% in the control group （P 〈 0.05）. [ Conclusion ] Combined treatment of kangfuxin solution with rabeprazole-based triple therapy is an effective solution for treatment which has a high clinical remission rate, can effectively relieve the inflammatory reaction, improve hemorheology index, and reduce the recurrence rate. It is worth further study in clinic.

关 键 词：康复新液 雷贝拉唑 消化性溃疡 炎性因子 血液流变学 

分 类 号：R573.1[医药卫生—消化系统]